

REMARKS

The claims have been amended to avoid the 35 U.S.C. § 112 grounds of rejection and the prior art grounds of rejection.

First, regarding the 35 U.S.C. § 112, first paragraph, ground of rejection, claim 1 has been amended to recite the liposome of the invention simply as a liposome to which a polyalkylene glycol and wild type human serum albumin are bonded. The terminology "non-modified serum albumin" has been deleted and, thus, avoids the rejection.

Second, regarding the 35 U.S.C. § 112, second paragraph, rejection, the amendment to claim 1 noted above also avoids the basis for this rejection. Claim 9 has been amended to precisely recite the process of the invention in terms of a Markush group of steps (A) - (F). Claim 9 has also been amended to add precisely recite each of the steps (A) to (F). The claims as amended are believed to be definite within the meaning of the requirements of the second paragraph of 35 U.S.C. § 112.

Third, regarding the rejection of the claims under 35 U.S.C. 102(b) as being anticipated by Kamps et al. (*Biochimica et Biophysica Acta* 1278 (1996); hereinafter "Kamps") and under 35 U.S.C. 103(a) as being unpatentable over Tardi et al. (*J. Immunological Methods*, 1997; hereinafter "Tardi"), the albumin of

RECEIVED
CENTRAL FAX CENTER

PATENT APPLN. NO. 10/534,874
SUBMISSION UNDER 37 C.F.R. §1.114

JUL 02 2008

PATENT
NON-FINAL

the liposome according to the present invention has been limited to wild type human serum albumin. The use of a wild type human serum albumin as now recited in the claims eliminates the possibility of the albumin that is administered from being recognized as an antigen.


Neither Kamps nor Tardi discloses or suggests a liposome to which a polyalkylene glycol and an albumin are bonded. where the albumin is a wild type human serum albumin.

Reconsideration and removal of the 35 U.S.C. 102(b) and 35 U.S.C. § 103(a) rejections of the claims are respectfully requested.

The foregoing is believed to be a complete and proper response to the Office Action dated April 2, 2007, and is believed to place this application in condition for allowance.

In the event any additional fees are required, please also charge our Deposit Account No. 111833.

Respectfully submitted,
KUBOVCIK & KUBOVCIK



Ronald J. Kubovcik
Reg. No. 25,401

Atty. Case No. IWT-001
Crystal Gateway 3
Suite 1105
1215 South Clark Street
Arlington, VA 22202
Tel: (703) 412-9494
Fax: (703) 412-9345
RJK/JBF